Cellular and molecular mechanisms of muscle atrophy

Paolo Bonaldo¹ and Marco Sandri¹,²

Skeletal muscle is a plastic organ that is maintained by multiple pathways regulating cell and protein turnover. During muscle atrophy, proteolytic systems are activated, and contractile proteins and organelles are removed, resulting in the shrinkage of muscle fibers. Excessive loss of muscle mass is associated with poor prognosis in several diseases, including myopathies and muscular dystrophies, as well as in systemic disorders such as cancer, diabetes, sepsis and heart failure. Muscle loss also occurs during aging. In this paper, we review the key mechanisms that regulate the turnover of contractile proteins and organelles in muscle tissue, and discuss how impairments in these mechanisms can contribute to muscle atrophy. We also discuss how protein synthesis and degradation are coordinately regulated by signaling pathways that are influenced by mechanical stress, physical activity, and the availability of nutrients and growth factors. Understanding how these pathways regulate muscle mass will provide new therapeutic targets for the prevention and treatment of muscle atrophy in metabolic and neuromuscular diseases.

Introduction

Muscles are the largest protein reservoir in the body. Muscles serve as a source of amino acids that can be used for energy production by various organs (including the heart, liver and brain) during catabolic periods, such as in cancer, sepsis, burn injury, heart failure and AIDS. However, excessive protein degradation in skeletal muscle, and the ensuing muscle loss (cachexia), is highly detrimental for the economy of the human body and can lead to death. Moreover, excessive loss of muscle mass is a poor prognostic indicator and can impair the efficacy of many different therapeutic treatments. Thus, cachexia ultimately aggravates diseases, and increases morbidity and mortality. The maintenance of healthy muscles is crucial for preventing metabolic disorders, maintaining healthy aging and providing energy to vital organs during stress conditions.

In adults, muscle mass and performance adapt to different pathophysiological conditions via activating pathways that regulate protein turnover. Muscle mass, like that of any other tissue, depends on protein turnover and cell turnover (Sartorelli and Fulco, 2004). In terms of muscle regeneration, the main players are satellite cells, a population of undifferentiated myogenic cells located between the basal lamina and the plasma membrane of muscle fibers. Although these cells play a major role in postnatal muscle growth, recent studies have challenged the idea that satellite cells are required for muscle mass maintenance and hypertrophy in adulthood (Amthor et al., 2009; Blauw et al., 2009; McCarthy et al., 2011; Raffaello et al., 2010; Sartori et al., 2009).

Atrophy is defined as a decrease in the size of a tissue or organ due to cellular shrinkage; the decrease in cell size is caused by the loss of organelles, cytoplasm and proteins. This Review discusses the latest findings and emerging concepts related to pathways controlling muscle atrophy in physiological and pathological conditions. In particular, we focus on the ubiquitin-proteasome machinery and the autophagy-lysosome machinery, the two most important cell proteolytic systems that control protein turnover in muscle. The involvement of these systems in muscle physiopathology, as well as the signaling pathways controlling their activity, have been unraveled only in recent years, and evidence indicates that these two processes play a pivotal role in regulating overall muscle homeostasis.

The ubiquitin-proteasome system

In muscle, the ubiquitin-proteasome system is required to remove sarcomeric proteins upon changes in muscle activity. A decrease in muscle mass is associated with: (1) increased conjugation of ubiquitin to muscle proteins; (2) increased proteasomal ATP-dependent activity; (3) increased protein breakdown that can be efficiently blocked by proteasome inhibitors; and (4) upregulation of transcripts encoding ubiquitin, some ubiquitin-conjugating enzymes (E2), a few ubiquitin-protein ligases (E3) and several proteasome subunits (reviewed in Lecker et al., 2006) (Fig. 1). The human genome encodes more than 650 ubiquitin ligases (Lee and Goldberg, 2011), which are involved in the precise regulation of different cellular processes, and dramatic progress has been made recently in elucidating the roles of different E3s in regulating metabolism, transcription, cell cycle, oncogenesis and muscle size. Different E2-E3 pairs degrade different proteins; the specificity of E3s for certain groups of proteins provides exquisite selectivity to this degradation. The amount of different E2 and E3 proteins varies between tissues types and under different physiological conditions,
but it is still unknown which specific E2s and E3s normally operate in muscle. Among the known E3s, only a few of them are muscle-specific and are upregulated during muscle loss (Sacheck et al., 2007).

A major contribution to the identification of which ubiquitin ligases are involved in muscle atrophy was provided by pioneering gene expression profiling performed independently by the groups of Alfred L. Goldberg and David J. Glass (Gomes et al., 2001; Bodine et al., 2001a). Comparing gene expression in different models of muscle atrophy led to the identification of a subset of genes that are commonly up- or downregulated in atrophying muscle. Because the diverse disease models used for these microarray experiments (including diabetes, cancer cachexia, chronic renal failure, fasting and denervation) have muscle atrophy in common, the commonly up- or downregulated genes are believed to regulate the loss of muscle components and are called atrophy-related genes or ‘atrogenes’ (Sacheck et al., 2007). Together, these findings revealed that muscle atrophy is an active process controlled by specific signaling pathways and transcriptional programs. Furthermore, the genes induced most strongly were found to encode two muscle-specific ubiquitin ligases, atrogin-1 (also known as MAFbx) and MuRF1 (Bodine et al., 2001a; Gomes et al., 2001) (Fig. 1). Notably, the transcription factor myogenin, an essential regulator of muscle development, is required for the maximal activation of these two genes, at least during denervation (Moresi et al., 2010).

Valuable information on the role of specific components of the ubiquitin-proteasome system in muscle was obtained by generating genetically modified animals (see Table 1). Mice lacking atrogin-1 and MuRF1 are resistant to muscle atrophy induced by denervation (Bodine et al., 2001a). Moreover, knockdown of atrogin-1 prevents muscle loss during fasting (Cong et al., 2011), whereas MuRF1 knockout mice (but not atrogin-1 knockout mice) are resistant to dexamethasone-induced muscle atrophy (Baehr et al., 2011). However, only a few muscle proteins have been identified as substrates for atrogin-1 thus far, and they all seem to be involved in growth-related processes or survival pathways. Atrogin-1 promotes degradation of MyoD, a key muscle transcription factor, and of eIF3f, an important activator of protein synthesis (Csibi et al., 2010; Tintignac et al., 2005) (Fig. 1). In the heart, atrogin-1 ubiquitylates and reduces the levels of calcineurin A, an important factor that triggers cardiac hypertrophy in response to pressure.
overload (Li et al., 2004). Conversely, MuRF1 was reported to interact and control the half-life of important muscle structural proteins, including troponin I (Kedar et al., 2004), myosin heavy chains (Clarke et al., 2007; Fieltz et al., 2007), myosin binding protein C and myosin light chain (Cohen et al., 2009) (Fig. 1).

Presumably, several other E3s are activated during atrophy that promote the clearance of soluble cell proteins and limit anabolic processes. A recent paper reported Trim32 as a crucial E3 ligase for the degradation of thin filaments (actin, tropomyosin and troponins), α-actinin and desmin (Cohen et al., 2012). However, Trim32 knockout mice are not protected from atrophy, but show an impairment in the recovery of muscle mass after atrophy (Kudryashova et al., 2012). Another ligase that seems to play an important role in atrophy is TRAF6 (Paul et al., 2010), an E3 ubiquitin ligase that mediates the conjugation of Lys63-linked polyubiquitin chains to its target proteins. Lys48-linked polyubiquitin chains are a signal for proteasome-dependent degradation, but they have other additional functions, such as regulating certain signaling pathways (e.g. modulating nuclear factor-κB (NFkB) activity) and being involved in autophagy-dependent cargo recognition via interacting with the scaffold protein p62 (also known as SQSTM1) (Kirkin et al., 2009; Komatsu et al., 2007; Pankiv et al., 2007). Notably, muscle-specific TRAF6 knockout mice have a decreased amount of polyubiquitylated proteins and almost no Lys63-polyubiquitylated proteins in starved muscles (Paul et al., 2012). TRAF6 knockout mice are resistant to muscle loss induced by denervation, cancer or starvation (Kumar et al., 2012; Paul et al., 2012; Paul et al., 2010). The mechanism of this protection involves both direct and indirect effects of TRAF6 on protein breakdown. In fact, TRAF6-mediated ubiquitylation is required for the optimal activation of JNK, AMPK, FoxO3 and NFB (Paul et al., 2012). All of these factors are crucial regulators of atrogin-1 and MuRF1 expression (discussed in more detail below). Moreover, they also control the expression of several autophagy-related genes. Inhibition of TRAF6 reduces their maximal induction, thereby preserving muscle mass under catabolic conditions.

Another ligase that is involved in the ubiquitylation of filamin C, a muscle protein found in the Z-line, is CHIP (Arndt et al., 2010). However, CHIP-mediated ubiquitylation causes a lysosomal-degradation of filamin C. Filamin is a protein that undergoes unfolding and refolding cycles during muscle contraction and is therefore prone to irreversible damage (Arndt et al., 2010). Alterations to filamin structure trigger the binding of the co-chaperone BAG3, which carries a complex made up of the chaperones Hsc70 and HspB8, as well as the ubiquitin ligase CHIP. CHIP ubiquitylates BAG3 and filamin, which are recognized and delivered to the autophagy system by p62 (Fig. 2) (Arndt et al., 2010). Interestingly, filamin B is controlled, at least during myogenesis, by another ubiquitin ligase, ASB2β, which is mainly expressed in muscle cells. In this case, the ubiquitylation of filamin B by ASB2β leads to proteasome-dependent degradation (Bello et al., 2009).

In skeletal muscle, E3 ligases can also have important regulatory functions on signaling pathways. For example, it was recently found that the ubiquitin ligase Fbxo40 regulates anabolic signals (Shi et al., 2011). Fbxo40 ubiquitylates and affects the degradation of IRS1, a downstream effector of insulin-receptor-mediated signaling (Fig. 1). Inhibition of Fbxo40 by RNAi induces hypertrophy in myotubes, whereas Fbxo40 knockout mice display bigger muscle fibers (Shi et al., 2011).

Although some of the E3 ligases involved in muscle protein ubiquitylation and breakdown have now been identified, still little is known about how ubiquitylated proteins are recognized and delivered to the proteasome. A recent report identified ZNF216 as an important player in the recognition and delivery to the proteasome of ubiquitylated proteins during muscle atrophy (Fig. 1). Interestingly, ZNF216 is upregulated by FoxO transcription factors in atrophying muscles, and ZNF216-deficient mice are partially resistant to muscle loss during denervation. The absence of ZNF216 in muscle leads to the accumulation of polyubiquitylated proteins (Hishiya et al., 2006).

Much research in this field is focused on the ubiquitylation process, but little is known about the role of the de-ubiquitylating system and its contribution to muscle atrophy. The largest class of de-ubiquitylating enzymes are the ubiquitin-specific processing proteases (USPs) and, thus far, only two (USP14 and USP19) have been found to be upregulated in atrophying muscles (Fig. 1) (Combares et al., 2005; Gomes et al., 2001). Knocking down USP19 expression in myotubes results in a decrease in protein degradation and reverts dexamethasone-induced loss of myosin heavy chain (Sundaram et al., 2009).

The autophagy-lysosome system

Autophagy plays a crucial role in the turnover of cell components both in constitutive conditions and in response to various stimuli, such as cellular stress, nutrient deprivation, amino acid starvation and cytokines (Mizushima et al., 2008). Three different mechanisms have been described in mammals for the delivery of the autophagic cargo to lysosomes: macroautophagy, chaperone-mediated autophagy (CMA) and microautophagy (Fig. 2). Thus far, most data on the role of the autophagic process in muscle are related to macroautophagy. Although it is still unknown whether microautophagy occurs in skeletal muscle, some findings indicate that microautophagy can participate in glycogen uptake into lysosomes when macroautophagy is blocked (Raben et al., 2008; Takikita et al., 2010). CMA has raised interest owing to its potential role in aging, neurodegenerative disorders and lysosomal storage diseases (Kon and Cuervo, 2010); however, whether it has roles in muscle homeostasis or atrophy is still largely unknown. In a study analyzing the contribution of CMA to protein breakdown in various organs of fasted rats, it was speculated that increased proteolysis in the liver and heart of fasted animals involves activation of CMA, but that this does not occur in skeletal muscles (Wing et al., 1991). The involvement of CMA in muscle homeostasis is an issue that needs to be addressed in detail in the coming years.

Autophagy was first described many years ago, but its involvement in muscle protein breakdown during atrophy was not recognized for a long time. Early evidence showed that lysosomal degradation contributes to protein breakdown in denervated muscle (Furuno et al., 1990; Schiaffino and Hanzliková, 1972). Moreover, cathepsin L, a lysosomal protease, was shown to be upregulated during muscle atrophy (Deval et al., 2001). The development of molecular and imaging tools to follow autophagosome formation has greatly improved the characterization of autophagy in normal and atrophying muscles (Klionsky et al., 2008). In fact, analysis of different organs revealed...
| Gene product                  | Mouse model      | Phenotype                                                                 | Reference                                 |
|------------------------------|------------------|---------------------------------------------------------------------------|-------------------------------------------|
| Ubiquitin-proteasome         |                  |                                                                           |                                           |
| Atrogin1 KO                  |                  | No phenotype, but protection from denervation-induced atrophy             | Bodine et al., 2001                      |
| MuRF1 KO                     |                  | No phenotype, but protection from denervation-induced atrophy             | Bodine et al., 2001                      |
| MuRF1 + MuRF2 Double KO      |                  | Muscle hypertrophy                                                        | Witt et al., 2008                        |
| Fbxo40 KO                    |                  | Muscle hypertrophy                                                        | Shi et al., 2011                         |
| ZNF216 KO                    |                  | No phenotype, but protection from denervation-induced atrophy             | Hishiya et al., 2006                     |
| Autophagy-lysosome           |                  |                                                                           |                                           |
| Atg5 Muscle-specific KO      |                  | Muscle weakness, atrophy, myopathic phenotype                              | Raben et al., 2008                       |
| Atg7 Muscle-specific KO, inducible muscle-specific KO |                  | Muscle weakness, atrophy, myopathic phenotype, increased muscle loss during denervation and fasting | Masiero et al., 2009                     |
| NAF-1 KO                     |                  | Increased autophagy, decreased muscle strength                            | Chang et al., 2012                       |
| Lamp2 KO                     |                  | Accumulation of autophagic vesicles in many tissues, including skeletal muscles | Tanaka et al., 2000                      |
| IGF1-Akt signaling pathway   |                  |                                                                           |                                           |
| IGF1 Muscle-specific transgenic |              | Muscle hypertrophy, protection against muscle loss during senescence, higher muscle regenerative capability during aging, protection from heart failure-induced atrophy, protection from angiotensin II-induced muscle wasting | Musaro et al., 2001; Schulze et al., 2005; Song et al., 2006 |
| IGF1 receptor                | Muscle-specific dominant negative | Delayed postnatal muscle growth, compensatory hyperplasia                | Fernandez et al., 2002                   |
| Akt1 Muscle-specific inducible transgenic |              | Muscle hypertrophy, protection from atrophy, long-term induction causes muscle degeneration | Lai et al., 2004; Mammucari et al., 2007; Izumiya et al., 2008 |
| Akt1 + Akt2 Double KO        |                  | Muscle atrophy, neonatal lethality                                         | Peng et al., 2003                        |
| mTOR Muscle-specific KO      |                  | Dystrophic phenotype                                                       | Risson et al., 2009                      |
| Raptor Muscle-specific KO    |                  | Dystrophic phenotype                                                       | Bentzinger et al., 2008                  |
| Rictor Muscle-specific KO    |                  | No phenotype                                                               | Bentzinger et al., 2008                  |
| Raptor + Rictor Muscle-specific double KO |              | Dystrophic phenotype                                                       | Bentzinger et al., 2008                  |
| FoxO1 Muscle-specific transgenic |              | Muscle atrophy                                                             | Kamei et al., 2004                       |
| FoxO1 Muscle-specific KO     |                  | Slow-to-fast myofiber switch                                               | Kitamura et al., 2007                    |
| FoxO3 Inducible KO           |                  | Normal                                                                    | Paik et al., 2007                        |
| TGFβ-myostatin signaling pathway |              | Muscle hypertrophy                                                        | McPherron et al., 1997; Grobet et al., 2003 |
| Myostatin Total KO, muscle-specific KO |              | Muscle hypertrophy                                                        | McPherron et al., 1997; Grobet et al., 2003 |
| Myostatin Muscle-specific transgenic |              | Moderate muscle atrophy in males                                           | Reisz-Porszasz et al., 2003              |
| ActRIIB Muscle-specific dominant negative |              | Muscle hypertrophy                                                        | Lee and McPherron, 2001                  |
| Follistatin Muscle-specific transgenic |              | Muscle hypertrophy                                                        | Lee and McPherron, 2001                  |
| Myostatin + FLRG Myostatin KO + muscle-specific FLRG transgenic |              | Marked muscle hypertrophy                                                 | Lee, 2007                                |
| Inflammatory cytokines and NFκB signaling pathway |              |                                                                           |                                           |
| TRAF6 Muscle-specific KO     |                  | No phenotype, but protection from denervation- and starvation-induced atrophy, protection from cancer cachexia | Paul et al., 2010; Paul et al., 2012     |
| TWEAK Muscle-specific transgenic |              | Muscle atrophy                                                            | Mittal et al., 2010                      |
| TWEAK KO                     |                  | No phenotype, but protection from denervation-induced atrophy             | Mittal et al., 2010                      |
| IKKβ (IKK2) Muscle-specific transgenic |              | Muscle atrophy                                                            | Cai et al., 2004                         |
| IKKβ (IKK2) Muscle-specific KO |                  | Increased muscle strength, protection from denervation-induced atrophy    | Mourkioti et al., 2006                   |
| p105/p50 (Nfkβ1) KO          |                  | No phenotype, but protection from unloading-induced atrophy               | Hunter and Kandarian, 2004               |
| Bcl3 KO                      |                  | No phenotype, but protection from unloading-induced atrophy               | Hunter and Kandarian, 2004               |
that skeletal muscle is one of the tissues with the highest rates of vesicle formation during fasting. Interestingly, fast glycolytic muscles display a higher content of autophagosomes than slow β-oxidative muscles (Mizushima et al., 2004). It is now known that myofiber atrophy induced by in vivo overexpression of constitutively active FoxO3 requires autophagy, and siRNA-mediated knockdown of LC3 (a protein that contributes to autophagosome formation) partially prevents FoxO3-mediated muscle loss (Mammucari et al., 2007). Other genetic models have confirmed the role of autophagy during muscle atrophy. For example, oxidative stress induced by the muscle-specific expression of a mutant superoxide dismutase protein (SOD1G93A) causes muscle atrophy mainly by activating autophagy, and attenuation of autophagy by shRNA-mediated knockdown of LC3 partially prevents FoxO3-mediated autophagy by Bnip3 contributes to mitochondrial remodeling (Chang et al., 2012).

Autophagy is primarily considered to be a non-selective degradation pathway, but the significance of more selective forms of autophagy is becoming increasingly evident. Indeed, autophagy can trigger the selective removal of specific organelles, such as mitochondria via mitophagy. In mammals, parkin, PINK1, Bnip3 and Bnip3L have been shown to regulate mitophagy, and inactivation of the genes encoding these proteins leads to abnormal mitochondria (Fig. 2) (Bothe et al., 2000; Hara et al., 2006). PINK1 recruits parkin to mitochondria, where parkin promotes mitophagy through ubiquitylation of outer mitochondrial membrane proteins that are recognized by p62, which brings autophagic vesicles to ubiquitylated mitochondrial proteins (Narendra and Youle, 2011; Youle and Narendra, 2011). Bnip3 and Bnip3L reportedly bind directly to LC3, and can therefore recruit the growing autophagosome to mitochondria (Hanna et al., 2012; Novak et al., 2010). In atrophying muscle, the mitochondrial network is dramatically remodeled following fasting or denervation, and autophagy via Bnip3 contributes to mitochondrial remodeling (Romanello et al., 2010; Romanello and Sandri, 2010). Expression of the fission machinery is sufficient to cause muscle wasting in mice, whereas inhibition of mitochondrial fission prevents muscle loss during denervation, indicating that disruption of the mitochondrial network is a crucial amplifying loop of the muscle atrophy program (Romanello et al., 2010; Romanello and Sandri, 2010). Conversely, impairment of basal mitophagy is deleterious to muscle homeostasis, and leads to the accumulation of damaged and dysfunctional mitochondria (Grunati et al., 2010). Besides mitophagy, other forms of selective autophagy probably play important roles in the maintenance of skeletal muscle homeostasis. For example, a proper rate of nucleophagia seems essential for nuclear remodeling of muscle fibers, as indicated by nuclear envelopepathies, a group of genetic disorders characterized by increased nuclear fragility and giant autophagosomes that contain nuclear components (Park et al., 2009).

Although available data are still limited to a few components of the autophagic machinery, the phenotypes of mice with muscle-specific inactivation of genes encoding autophagy-related proteins clearly demonstrate the essential role of autophagy in muscle homeostasis (see Fig. 2 and Table 1). Ablation of Atg7, the unique E1 enzyme of the autophagic machinery, causes disorganized sarcomeres and activation of the unfolded protein response, which in turn triggers myofiber degeneration; this phenotype is associated with complete inhibition of autophagosome formation, leading to abnormal mitochondria, oxidative stress and accumulation of polyubiquitylated proteins (Masiero et al., 2009). These Atg7-null mice are affected by muscle weakness and atrophy, and they display several signs of myopathy. Another study showed that suppression of autophagy exacerbates fasting- and denervation-induced atrophy in Atg7-null mice (Masiero and Sandri, 2010). A similar phenotype was observed in mice with muscle-specific ablation of Atg5, another crucial component of the autophagy machinery (Raben et al., 2008). Another recent mouse study revealed that nutrient-deprivation autophagy factor-1 (Naf-1), a Bcl-2-associated autophagy regulator, is required for the homeostatic maintenance of skeletal muscle. Naf1-null mice display muscle weakness and markedly decreased strength, accompanied by increased autophagy, dysregulation of calcium homeostasis and enlarged mitochondria (Chang et al., 2012).

Recent genetic studies by the group of Eric N. Olson revealed a key role for histone deacetylases (HDACs) in the control of skeletal muscle homeostasis and autophagic flux (Moresi et al., 2012; Moresi et al., 2010) (Table 1). Muscle-specific ablation of both HDAC1 and HDAC2 results in partial perinatal lethality, and HDAC1/2 double-knockout mice surviving postnatally develop a progressive myopathy characterized by impaired autophagy. HDAC1 and HDAC2 were found to regulate muscle autophagy by inducing the expression of autophagy genes. Notably, feeding HDAC1/2 knockout mice a high-fat diet releases the block in autophagy and prevents myopathy (Moresi et al., 2012). Another study by the same group also revealed roles for HDAC4 and HDAC5, as well as for the transcriptional muscle regulator myogenin, in modulating atrophy following denervation (Moresi et al., 2010). These studies
demonstrated that myogenin activates the expression of the E3 ubiquitin ligases atrogin-1 and MuRF1, and that myogenin knockout mice fail to upregulate atrogin-1 and MuRF1 following denervation and are protected from atrophy. Similarly, mice lacking both HDAC4 and HDAC5 in skeletal muscle fail to upregulate myogenin and preserve muscle mass following denervation (Moresi et al., 2010).

The crucial role of the autophagy-lysosome system in skeletal muscles is confirmed by the fact that alterations to this process contribute to the pathogenesis of several genetic muscle diseases. Autophagy has a dual role in muscle homeostasis: it can be detrimental and contribute to muscle degeneration, but can also be a compensatory mechanism for cell survival. Congenital muscular dystrophies that are linked to the extracellular matrix (ECM) proteins collagen VI and laminin-2 illustrate the opposite effects that autophagy can have in skeletal muscles (Carmignac et al., 2011; Grumati et al., 2010). Our recent work indicated that autophagy plays a protective role against muscle weakness and wasting in Bethlem myopathy and Ullrich congenital muscular dystrophy, which are two inherited muscle disorders associated with collagen VI deficiency (Bernardi and Bonaldo, 2008; Grumati et al., 2010). A failure of the autophagic machinery is responsible for the inefficient removal and persistence of altered mitochondria in myofibers of Col6a1-null mice, and of Bethlem and Ullrich patients. Notably, reactivation of the autophagic flux in collagen-VI-deficient muscles (through diet or with pharmacological tools) can eliminate altered organelles and rescue the myopathic phenotype, showing promising therapeutic potential for counteracting muscle atrophy and weakness in these diseases (Grumati et al., 2010).

Fig. 2. Macrophagy, microautophagy and chaperone-mediated autophagy (CMA), and their contribution to protein degradation and organelle removal in skeletal muscle. (A) Macrophagy is triggered by the activation of a regulatory complex (containing Vps34, Beclin 1, Vps15, Ambra1 and Atg14) that induces LC3 recruitment to the nascent autophagosome (isolation membrane). Selective removal of mitochondria (mitophagy; a specific form of macroautophagy) requires the PINK1-parkin complex and Bnip3 factors. Proteins that are committed for lysosomal degradation (including BAG3 and filamin, shown here) are labeled by polyubiquitin chains and delivered to the autophagosome by the p62 scaffold protein. (B) Microautophagy involves the direct engulfment of small portions of cytoplasm into lysosomes. Glycogen (Glyc) is reportedly taken up and broken down by microautophagy in skeletal muscle. (C) In CMA, proteins that are damaged by different agents, such as reactive oxygen species (ROS), expose a specific amino acid sequence (the KFERQ motif) that is recognized by the Hsc70 chaperone, which in turn delivers them to the lysosome via interaction with Lamp2a receptors. Dotted lines depict pathways whose molecular mechanisms and roles in adult skeletal muscle have not yet been fully defined.
Grumati et al., 2011a). However, the full details of the molecular axis that transduces collagen VI signals from the ECM to the autophagy machinery remain to be elucidated.

Further studies revealed that abnormal regulation of autophagy is involved in the pathogenesis of other mouse models of muscular dystrophies. Unlike mice with collagen VI deficiency, dy3K/dy3K mice (which lack laminin-2 and represent a model for merosin-deficient congenital muscular dystrophy type 1A [MDC1A]) display a general upregulation of autophagy-related genes, and pharmacological inhibition of autophagy significantly improves their dystrophic phenotype (Carmignac et al., 2011). Therefore, inappropriate regulation of autophagy is pathogenic in the two most common forms of congenital muscular dystrophy, which are both linked to deficiency of ECM proteins (collagen IV or laminin-2). How the absence of either of these two ECM proteins results in such opposing effects on autophagy remains undefined, but it is clear that alterations to the main components of muscle endomysial ECM have a marked impact on the regulation of autophagy.

Accumulation of autophagosomes occurs in many myopathies and represents the major feature of a group of muscle disorders named autophagic vacuolar myopathies (Malicdan et al., 2008). These myopathies are characterized by mutation of genes encoding proteins involved in lysosomal function, and include Pompe disease (caused by a defect in lysosomal acid β-glucosidase), Danon disease (caused by mutations of the LAMP2 gene) and X-linked myopathy with excessive autophagy (XMEA; which is associated with mutations of the VMA21 gene) (Malicdan et al., 2008; Ramachandran et al., 2009). It remains to be established whether accumulation of autophagosomes in these myopathies contributes to muscle damage or, conversely, whether it is a compensatory effect. Indeed, for many years the pathogenic defects of Pompe disease were attributed to impairment and rupture of lysosomes. However, this view was challenged by the newly proposed idea that the massive accumulation of autophagosomes (resulting from defective autophagy) is the main event causing myofibrillar disorganization and altered endocytic trafficking (Fukuda et al., 2006a; Fukuda et al., 2006b). Recently, additional inherited muscle disorders were shown to be related to increased autophagy. For example, mutations that inactivate MTMR14 (also known as Jumpy), a phosphatase counteracting the action of Vps34 in autophagosome formation and reducing the autophagy flux, have been associated with centronuclear myopathy (Vergne et al., 2009). Jumpy, a phosphatase counteracting the action of Vps34 in autophagosome formation and reducing the autophagy flux, have been associated with centronuclear myopathy (Vergne et al., 2009). Additionally, forced expression of proliferator-activated receptor gamma coactivator-1α (PGC1α; a master gene of mitochondrial biogenesis) ameliorates loss of muscle mass and prevents the age-related increase in autophagy (Wenz et al., 2009). An interesting link between autophagy and aging was recently described in Drosophila, where the maintenance of a normal autophagic flux in aged muscles was found to induce a beneficial extension of lifespan. Selective activation of autophagy in skeletal muscle via FoxO prevents accumulation of protein aggregates and, consequently, muscle weakness, thus providing the first genetic evidence correlating FoxO, autophagy and healthy muscles to lifespan extension (Demosits and Perrimon, 2010).

Other recent work has demonstrated a link between physical exercise and autophagy in muscle. We have shown that physical exercise is very effective in stimulating autophagy in skeletal muscles, and that the accompanying clearance of damaged cell components and dysfunctional mitochondria is crucial for muscle homeostasis (Grumati et al., 2011b). Further work extended these observations and demonstrated that exercise-induced autophagy plays an important and previously unrecognized role in muscle metabolism (He et al., 2012). These findings provide a mechanism for explaining the well-known beneficial effects of physical activity in healthy individuals.

**Signaling pathways regulating muscle atrophy**

Many recent findings have highlighted a complex scenario whereby an intricate network of signaling pathways regulates the size of myofibers and the contractile performance of muscle. Intriguingly, these different pathways crosstalk and modulate one another at different levels, coordinating protein synthesis and degradation simultaneously (Fig. 3). Below, we discuss the involvement of four major pathways (IGF1-Akt-FoxO, myostatin, NFκB and glucocorticoids) in muscle atrophy.

**IGF1-Akt-FoxO signaling**

Insulin-like growth factor 1 (IGF1), a circulating growth factor, is also produced locally by many tissues, including skeletal muscle (reviewed in Schiaffino and Mammucari, 2011). Muscle-specific overexpression of a locally acting IGF1 isoform in mice showed that localized IGF1 expression sustains muscle growth and regeneration (Musarò et al., 2001) (Table 1). Indeed, these mice have muscle hypertrophy and display higher regenerative capacity and maintenance of muscle mass during aging (Musarò et al., 2001). Other studies have shown that IGF1 and/or insulin signaling can suppress protein breakdown while promoting muscle growth
Furthermore, IGF1 transgenic mice are resistant to muscle atrophy induced by angiotensin treatment, and to cardiac cachexia (Schulze et al., 2005; Song et al., 2005). Furthermore, local IGF1 injection is sufficient to block disuse atrophy (Stitt et al., 2004). In these models of muscle loss, IGF1 completely suppressed the induction of the two crucial ubiquitin ligases.

Additional data supporting the role of the IGF1 pathway in regulating muscle atrophy derive from studies of Akt. Electroporation of constitutively active Akt in adult myofibers completely blocks muscle atrophy induced by denervation (Stitt et al., 2004). In these models of muscle loss, IGF1 completely suppressed the induction of the two crucial ubiquitin ligases.

Moreover, Akt controls both protein synthesis, via mTOR, and protein degradation, via transcription factors of the FoxO family (Fig. 3). mTOR is a crucial kinase downstream of insulin and nutrient-sensitive pathways required for cell growth. mTOR is part of two different complexes, the rapamycin-sensitive TORC1 complex, which contains Raptor, and the rapamycin-insensitive TORC2 complex, which contains Rictor (for a review, see Laplante and Sabatini, 2012). The phenotypes of mice with muscle-specific ablation of mTOR, Raptor and Rictor provide valuable information (Table 1): Rictor knockout muscles do not show any overt phenotype, but Raptor- and mTOR-deficient mice display a...
progressive muscular dystrophy phenotype (Bentzinger et al., 2008; Raben et al., 2008; Risson et al., 2009).

The upregulation of atrogin-1, MuRF1 and several autophagy-related genes is normally blocked by Akt through negative regulation of FoxO transcription factors (Lee et al., 2004; Sandri et al., 2004; Stitt et al., 2004). The FoxO family in skeletal muscle is comprised of three isoforms: FoxO1, FoxO3 and FoxO4. Akt phosphorylates FoxO proteins, promoting their export from the nucleus to the cytoplasm. As predicted, the reduced activity of the Akt pathway observed in different models of muscle atrophy results in decreased levels of phosphorylated FoxO in the cytoplasm and a marked increase of nuclear FoxO (reviewed in Calnan and Brunet, 2008) (Fig. 3). The translocation and activity of FoxO members is required for the upregulation of atrogin-1 and MuRF1, and FoxO3 is sufficient to promote atrogin-1 expression and muscle atrophy when transfected into skeletal muscles in vivo (Sandri et al., 2004). FoxO1 transgenic mice show markedly reduced muscle mass and fiber atrophy, further supporting the notion that FoxO proteins are sufficient to promote muscle loss (Kamei et al., 2004; Southgate et al., 2007). In contrast, FoxO knockdown by RNAi can block the upregulation of atrogin-1 expression during atrophy and muscle loss (Liu et al., 2007; Sandri et al., 2004). Cross-talk between protein breakdown and protein synthesis is not limited to Akt, but also involves FoxO. Activation of FoxO in Drosophila muscle upregulates 4E-BP1 (Demontis and Perrimon, 2010) and represses mTOR via sestrin (Lee et al., 2010). Consistently, in mammals, FoxO3 reduces total protein synthesis in adult muscle (Reed et al., 2012). Thus, when Akt is active, protein breakdown is suppressed, and when FoxO is induced, protein synthesis is further suppressed. This is not trivial, because FoxO activity is regulated by several different post-translational modifications, including phosphorylation, acetylation, and mono- and polyubiquitination (Huang and Tindall, 2007). Indeed, recent evidence suggests that acetylation negatively regulates FoxO3 activity, whereas it has no effect on FoxO1 (Senf et al., 2011). Mutants of FoxO3 that mimic acetylation show a cytosolic localization and a lower ability to induce transcription of the gene encoding atrogin-1, and to induce muscle atrophy (Bertaggia et al., 2012). Most of these regulatory mechanisms are Akt-independent and might play a role in muscle atrophy induced by oxidative or energy stress (see below).

Other findings have revealed a connection between AMPK and FoxO3 (Fig. 3). AMPK phosphorylates several Akt-independent sites on FoxO3, thereby stimulating its transcriptional activity (Greer et al., 2007a; Greer et al., 2007b). Indeed, treatment of muscle cultures with AICAR, an activator of AMPK, increases protein breakdown and atrogin-1 expression via the FoxO family (Nakashima and Yakabe, 2007). We recently found that FoxO3 is activated via AMPK in myofibers to induce the expression of atrogin-1 and MuRF1 in conditions of energy stress (Romanello et al., 2010). Activation of AMPK also leads to induction of some autophagy-related genes, such as those coding for LC3 and Bnip3.

Increased oxidative stress occurs during denervation and hindlimb suspension. During these disuse conditions, nNOS moves from the sarcosome, where it is bound to the dystrophin-glycoprotein complex, to the cytosol. Free cytosolic nNOS induces oxidative stress and enhances FoxO3-mediated transcription of atrogin-1 and MuRF1, thereby causing muscle loss (Suzuki et al., 2007). Interestingly, the NFκB pathway is not involved in nNOS-mediated muscle atrophy (Suzuki et al., 2007). Similarly, when DHPR is reduced in adult muscle by RNA interference (RNAi), it also triggers atrophy via nNOS relocalization and FoxO3 activation (Pietri-Rouzel et al., 2010). However, in this latter setting, the genes upregulated by FoxO3 are those coding for the autophagy regulators LC3, Vps34 and Bnip3, and the gene encoding the lysosomal enzyme cathepsin L. In humans, the diaphragm of patients that are mechanically ventilated undergoes rapid atrophy by activating different proteolytic systems, including autophagy (Levine et al., 2008). Prolonged mechanical ventilation induces diaphragm disuse that, in turn, leads to activation of autophagy through Akt inhibition and FoxO1 induction. Interestingly, oxidative stress is increased and therefore contributes to FoxO activation in this setting of disuse-mediated atrophy.

FoxO activity is also modulated by direct or indirect actions of cofactors and by interacting with other transcription factors. FoxO has been found to interact with PGC1α, a critical cofactor for mitochondrial biogenesis (Piigserver et al., 2003; Wu et al., 1999). Maintaining high levels of PGC1α during catabolic conditions (either in transgenic mice or by transfecting adult myofibers) spares muscle mass during denervation, fasting, heart failure, aging and sarcopenia—similar to the effect observed with expression of constitutively active FoxO3 (Geng et al., 2011; Sandri et al., 2006; Wenz et al., 2009). Similar beneficial effects were recently obtained by overexpression of PGC1β, a homolog of PGC1α (Brault et al., 2010). The positive action on muscle mass of these cofactors is due to the inhibition of autophagy-lysosome and ubiquitin-proteasome degradation systems. PGC1α and PGC1β reduce protein breakdown by inhibiting the transcriptional activity of FoxO3 and NFκB, but they do not affect protein synthesis. Thus, these cofactors prevent the excessive activation of proteolytic systems by inhibiting the action of the pro-atrophy transcription factors without perturbing the translational machinery.

We recently reported that the transcription factor JunB blocks atrophy and promotes hypertrophy in adult mouse muscles (Raffaello et al., 2010). Indeed, JunB can block myofiber atrophy of denervated tibialis anterior muscles and cultured myotubes induced by FoxO3 overexpression, dexamethasone treatment or starvation. In these conditions, JunB prevents the activation of atrogin-1 and partially that of MuRF1, thereby reducing the increase in overall protein degradation induced by activated FoxO3. Further analysis revealed that JunB does not inhibit FoxO3-mediated activation of the autophagy-lysosome system, but only the ubiquitin-proteasome degradation, through inhibiting atrogin-1 and MuRF1 induction during catabolic conditions. In fact, JunB directly binds FoxO3, thereby preventing its recruitment to the promoters of key atrogens. Moreover, JunB overexpression is sufficient to induce dramatic hypertrophy of myotubes and of adult muscle. These hypertrophic changes depend on increased protein synthesis, without affecting the basal rate of protein degradation. The growth-promoting effects mediated by JunB in muscle resemble the effects of inhibiting the transforming growth factor-β (TGFβ) pathway (Sartori et al., 2009; Trendelenburg et al., 2009). Indeed, JunB overexpression markedly suppresses myostatin expression in transfected myotubes and decreases the phosphorylation of Smad3, the transcription factor downstream of the myostatin-TGFβ signaling pathway (Raffaello et al., 2010).
Inflammatory cytokines and NFκB signaling

NFκB transcription factors, which play major roles as mediators of immunity and inflammation, are also expressed in skeletal muscle, where they mediate the effect of inflammatory cytokines, particularly tumor necrosis factor-α (TNFα), on muscle wasting and cachexia (reviewed in Peterson et al., 2011) (Fig. 3). In the inactive state, NFκB is sequestered in the cytoplasm by a family of inhibitory proteins called IκB. In response to TNFα, the IκB kinase (IKKβ) complex phosphorylates IκB, resulting in its ubiquitylation and proteasomal degradation. This leads to nuclear translocation of NFκB and activation of NFκB-mediated gene transcription (Peterson et al., 2011).

Muscle-specific overexpression of IKKβ in transgenic mice leads to severe muscle wasting mediated, at least in part, by the ubiquitin-ligase MuRF1, but not by atrogin-1 (Cai et al., 2004) (Table 1). In contrast, muscle-specific inhibition of NFκB by transgenic expression of a constitutively active IκB mutant does not induce an overt phenotype, but denervation atrophy is substantially reduced (Judge et al., 2007). Muscle atrophy induced by hindlimb unloading is likewise reduced in mice deficient for the p105/p50 subunit of NFκB (Hunter and Kandarian, 2004). However, TNFα and pro-inflammatory cytokines also cause insulin resistance and suppression of the IGF1-Akt pathway (de Alvaro et al., 2004; Dogra et al., 2007; Hirosumi et al., 2002). Therefore, Akt phosphorylation should always be explored when the NFκB pathway is perturbed, because Akt inhibition can substantially contribute to muscle atrophy. This concept is supported by the phenotype of IKKβ conditional knockout mice, which are resistant to muscle atrophy but show hyperphosphorylation of Akt (Mourikioti et al., 2006). The significance of decreased muscle atrophy following IKKβ ablation and the degree to which this effect is Akt dependent remain unclear. Nevertheless, these findings highlight the relevance of the crosstalk between the two pathways, and future studies are needed to elucidate the respective contributions of the IKKβ-NFκB and Akt-FoxO pathways to muscle atrophy.

A recent study revealed an unexpected connection between TNFα signaling and myogenin on MuRF1 and atrogin-1 expression: TNFα treatment causes upregulation of myogenin, MuRF1 and atrogin-1. Interestingly, a G-protein-coupled receptor blocks the TNFα-mediated myogenin upregulation by activating Gαq (Minetti et al., 2011) and the expression of muscle-specific ubiquitin ligases. However, the precise mechanisms of TNFα-mediated myogenin regulation, the interplay with Gαq and the implications for muscle wasting are still far from fully understood.

TNF-like weak inducer of apoptosis (TWEAK) is a member of the TNF superfamily and was recently found to induce muscle atrophy (Dogra et al., 2007; Mittal et al., 2010). TWEAK acts on responsive cells by binding to fibroblast growth factor-inducible 14 (Fn14), a small cell-surface receptor (Fig. 3). Fn14 is upregulated in denervated muscle, allowing NFXB activation and consequently MuRF1 (but not atrogin-1) expression (Mittal et al., 2010). TWEAK knockout mice display less atrophy than wild-type mice during denervation, as well as reduced NFXB activation and MuRF1 expression (Table 1). However, Fn14 levels do not increase in all conditions of muscle atrophy; for instance, Fn14 is not induced by dexamethasone treatment. Another important player in NFXB signaling is the ubiquitin ligase TRAF6, which is required for Fn14 upregulation during fasting (Paul et al., 2012). As noted earlier, TRAF6 is also required for the activation of FoxO3 and AMPK in starved muscles, and for the induction of ubiquitin-proteasome and autophagy-lysosome systems (Paul et al., 2012).

Myostatin and crosstalk with Akt

Myostatin, a member of the TGFβ family, is expressed and secreted predominantly by skeletal muscle, and functions as a negative regulator of muscle growth. Mutations of the myostatin gene lead to a hypertrophic phenotype in mice, sheep and cattle, and a loss-of-function mutation in the human myostatin gene was also found to induce increased muscle mass (Clop et al., 2006; Lee and McPherron, 2001; McPherron and Lee, 1997; Schuelke et al., 2004). The increase in muscle mass caused by loss of myostatin is a consequence of both hyperplasia (i.e. increased cell number) and hypertrophy (i.e. increased cell size) (Lee, 2004; Lee and McPherron, 1999; McPherron et al., 1997).

In contrast, the capacity of myostatin activation to trigger muscle atrophy is not obvious. Although an early report described severe (even fatal) atrophy when Chinese hamster ovary (CHO) cells engineered to express myostatin were injected into mouse skeletal muscle (Zimmers et al., 2002), these findings were not confirmed in transgenic mice. Muscle-specific overexpression of myostatin leads to only 20% atrophy (i.e. a 20% decrease in muscle mass) in males and no phenotype in females (Reisz-Porszasz et al., 2003) (Table 1). Electroporation experiments showed that myostatin expression in adult muscle induces a degree of atrophy comparable to that observed in transgenic mice (Durieux et al., 2007). These findings suggest that the CHO cells used by Zimmers et al. contributed to muscle atrophy by secreting cachectic factors, and that the myostatin pathway synergizes with other pathways. However, in muscle cell cultures, myostatin was reported to upregulate essential atrophy-related ubiquitin ligases; notably, this regulation was found to be FoxO dependent (McFarlane et al., 2006). In fact, myostatin treatment blocks the IGF1-P13K-Akt pathway and activates FoxO1, allowing increased expression of atrogin-1. This crosstalk between the two pathways does not require NFκB, whose inhibition does not prevent upregulation of atrogin-1 (McFarlane et al., 2006). Similarly, in cardiac cells, myostatin abrogates phenylephrine hypertrophic effects through Akt inhibition (Morissette et al., 2006). Furthermore, myostatin expression is controlled by FoxO1, supporting the concept that the myostatin pathway synergizes with Akt-FoxO signaling (Allen and Unterman, 2007).

Recent reports dissected the myostatin pathway both in vitro and in vivo, and showed that Smad2 and Smad3 are the transcription factors mediating myostatin effects on muscle mass (Lokiredy et al., 2011; Sartori et al., 2009; Trendelenburg et al., 2009) (Fig. 3). The downstream targets of Smad2 and Smad3 are not yet known, so the mechanisms of Smad-dependent atrophy remain to be established. Importantly, Smads can recognize the DNA sequence CAGAC, but their affinity is not sufficient to support unassisted binding to DNA. In addition, if their binding affinity for this simple sequence were higher, Smad proteins would decorate entire chromosomes. Therefore, activated Smads must associate with different DNA-binding cofactors for the recognition and regulation of specific target genes (Massagué et al., 2005). Interestingly, members of the FOXO family were found to play such a role (Gomis et al., 2006). Recent reports have identified an
Mechanisms of muscle atrophy

inhibitory effect of myostatin-Smad2/3 signaling on the IGF1-Akt-mTOR pathway (Amiriouche et al., 2009; Sartori et al., 2009; Trendelenburg et al., 2009), thereby supporting the idea that there is synergy between FoxOs and Smads to activate an atrophic program. However, the growth-promoting effects of myostatin inhibition seem to be independent of the Akt pathway (Goncalves et al., 2010). The mechanism through which myostatin inhibition leads to hypertrophy is a key issue that needs to be addressed to better understand the therapeutic potential of anti-myostatin drugs. A recent study showed that inhibition of myostatin by soluble ActRIIB prevents and fully reverses skeletal muscle loss and atrophy of the heart in tumor-bearing animals (Zhou et al., 2010). Such treatment dramatically prolongs the survival of these animals, suggesting potential therapeutic efficacy in patients with cancer cachexia.

Glucocorticoid-induced muscle atrophy and the control of protein homeostasis

Glucocorticoid levels are increased in many pathological conditions associated with muscle loss. Consistently, glucocorticoid treatment induces atrogin-1 and MuRF1 expression and muscle wasting in cell culture and in vivo (Bone et al., 2001b; Clarke et al., 2007; Sacheck et al., 2004; Sandri et al., 2004; Schakman et al., 2008). In contrast, adrenalectomy or treatment with a glucocorticoid receptor antagonist attenuates muscle loss in some diseases (Menconi et al., 2007; Schakman et al., 2008). The mechanisms of glucocorticoid-mediated muscle atrophy were recently unraveled (Fig. 3). Once in the nucleus, the glucocorticoid receptor activates the expression of two target genes, encoding REDD1 and KLF15 (Shimizu et al., 2011). REDD1 inhibits mTOR activity by sequestering 14-3-3 and increasing TSC1/2 activity. Inhibition of mTOR is permissive for the activation of an atrophy program via KLF15. Indeed, mTOR activation attenuates glucocorticoid-induced muscle atrophy. KLF15 is a transcription factor that is involved in several metabolic processes in skeletal muscle, for instance in the upregulation of the branched-chain aminotransferase 2 (BCAT2). KLF15 participates in muscle catabolism via transcriptional regulation of FoxO1, atrogin-1 and MuRF1. Moreover, KLF15 negatively affects mTOR through upregulation of BCAT2, which in turn induces branched-chain amino acid degradation. Interestingly, FoxO1 and glucocorticoid receptor cooperate to upregulate MuRF1 expression (Waddell et al., 2008).

Therapeutic perspectives for counteracting muscle atrophy

The mechanisms controlling muscle mass have attracted increasing interest in the scientific community because increased understanding of these can potentially help to tackle various clinical problems, including aging, the prognosis of many diseases, quality of life and sports medicine. The results of recent research offer new and exciting perspectives to the field, and have introduced several stimulating questions to the community, setting the foundation for future studies that will hopefully identify new therapeutic targets and drugs.

Several potentially interesting therapeutic targets have already been identified, although an effective drug that can counteract muscle wasting is not yet clinically available. The most interesting targets belong to the anabolic pathways and the ubiquitin-proteasome system. As we have discussed, Akt and its downstream targets seem to be at the intersection of several different pathways (see below), including β-adrenergic signaling, myostatin and JNK. Moreover, the IGF1-Akt axis is unique in that it controls both protein synthesis and protein degradation. Therefore, IGF1 analogs might be extremely useful for counteracting muscle loss and weakness. However, the same pathway plays major roles in other biological processes, including cell survival, and in other contexts it can promote tumorigenesis. Thus, the development of a new generation of IGF1 mimetics that specifically activate the Akt pathway in skeletal muscle is a goal for the field. Even if these are successfully developed, however, it should be considered that prolonged inhibition of protein degradation can have a major impact on protein quality control. Such agents could have major drawbacks, such as promoting the accumulation of misfolded or aggregate-prone proteins (Grumati et al., 2010; Masiero et al., 2009).

β-adrenergic agonists such as clenbuterol are considered pro-growth and anti-atrophic drugs. Most effects of clenbuterol are mediated by activating Akt-mTOR signaling (Kline et al., 2007), so the concerns associated with IGF1 stimulation can also be applied to β-adrenergic agonists. However, as noted earlier, a recent report revealed that the β-adrenergic signal might act via a different mechanism (involving hypertrophy induced by a G-protein-coupled receptor and Gαi2 through inhibition of GSK-3β and activation of p70S6K1) that is independent of the PI3K-Akt axis (Minetti et al., 2011). Notably, the contribution of p70S6K1 and its downstream target S6 to protein synthesis in muscle is uncertain, because S6K1 knockout mice show no impairment of polysome formation, protein synthesis or protein degradation (Mieulet et al., 2007). Therefore, S6 phosphorylation should not be considered a marker of protein synthesis, and we need a better understanding of which mTOR downstream targets are crucial regulators of protein synthesis in order to evaluate the role of this pathway in muscle growth and its potential in therapeutic approaches.

Another important factor that is currently being explored as a means to counteract muscle loss is myostatin. A recent report that inhibition of myostatin by using soluble ActRIIB prevents and fully reverses skeletal muscle loss, and prolongs the survival of tumor-bearing animals (Zhou et al., 2010), has opened the field to myostatin inhibition as a promising therapeutic approach. Despite the well-established growth-promoting action of myostatin inhibition, the anti-atrophic effect of myostatin blockade remains uncertain. In fact, expression of dominant-negative ActRIIB, or knockdown of Smad2 and Smad3, cannot prevent muscle loss during denervation (Sartori et al., 2009). Therefore, targeting the myostatin pathway might be better suited for muscle rehabilitation after injury than for prevention of muscle loss.

The last category of drug targets is represented by the proteasome system. Proteasome inhibitors have been successfully used to block atrophy in different animal models (Caron et al., 2011; Jamart et al., 2011; Supinski et al., 2009). However, the ubiquitin-proteasome system regulates many relevant biological processes and its prolonged inhibition might be detrimental for muscle cells. Indeed, patients chronically treated with bortezomib, a proteasome inhibitor that was approved by the FDA to treat multiple myeloma, display cardiac complications (Orciulo et al., 2007). Therefore, more specific approaches that can target the ubiquitin ligases
involved in ubiquitination and degradation of sarcomeric proteins should be pursued. Among the different ubiquitin ligases, MuRF1 and TRAF6 seem interesting candidates for developing specific inhibitors. However, ablation of MuRF1 or TRAF6 only partially protects from muscle loss during denervation in mice (Bodine et al., 2001a; Paul et al., 2010), indicating that other ubiquitin ligases are also involved in protein degradation. Moreover, it is still unknown whether different muscle atrophic conditions recruit different sets of ubiquitin ligases. Nonetheless, the findings of these last few years have greatly enhanced our knowledge of protein synthesis and degradation in skeletal muscle, and there is increasing hope that it will be possible to develop efficient therapeutic approaches for countering muscle wasting in the near future.

ACKNOWLEDGEMENTS

We apologize to colleagues whose studies were not cited owing to space limitations.

FUNDING

Our work is supported by grants from Telethon-Italy (GGP10225 and GGP11082 to PB; TCP04009 to M.S.), from the European Union (MYOCONTRACT, contract: 223576 of FP7 to MS; BIO-NMD FP7-HEALTH-241665 to PB), ERC (MyoPHAGY to M.S.), the Italian Ministry of Education, University and Research (to PB. and M.S.) and CARIPARO (to M.S. and P.B.).

REFERENCES

Allen, D. L. and Unterman, T. G. (2007). Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. Am. J. Physiol. Cell. Physiol. 292, C188-C199.

Amirouche, A., Durieux, A. C., Banzet, S., Koullmann, N., Bonnefoy, R., Mouret, C., Bigard, X., Peinquin, A. and Freyssenet, D. (2009). Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle. Endocrinology 150, 286-294.

Amthor, H., Otto, A., Vulin, A., Rochat, A., Dumonceaux, J., Garcia, L., Mousel, E., Houdé, C., Macharia, R., Friedrichs, M. et al. (2005). Muscle hypertrophy driven by myostatin blockade does not require stem/precursor-cell activity. Proc. Natl. Acad. Sci. USA 102, 7479-7484.

Arndt, V., Dick, N., Tawo, R., Dreiseidler, M., Wenzel, D., Hesse, M., Fürst, D. O., Arndt, V., Dick, N., Tawo, R., Dreiseidler, M., Wenzel, D., Hesse, M., Fürst, D. O., Börner, G. W., Haspel, J. A., Smith, C. L., Wiener, H. H. and Burden, S. J. (2000). Selective expression of Cre recombinase in skeletal muscle fibers. Genesis 26, 165-166.

Brault, J. J., Jespersen, J. G. and Goldberg, A. L. (2010). Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy. J. Biol. Chem. 285, 19460-19469.

Cai, D., Frantz, J. D., Tawa, N. E., Jr, Melendez, P. A., Oh, B. C., Lidov, H. G., Hasselgren, P. O., Frontera, W. R., Lee, J., Glass, D. J. et al. (2004). IKBKapα-kappaB activation causes severe muscle wasting in mice. Cell 119, 285-298.

Calnan, D. R. and Brunet, A. (2008). The Foxo code. Oncogene 27, 2276-2288.

Carmignac, V., Svensson, M., Körner, Z., Elowsson, L., Matsumura, C., Gawlik, K. L., Allamand, V. and Durbeej, M. (2011). Autophagy is increased in lamin a2 chain-deficient muscle and its inhibition improves muscle morphology in a mouse model of MDC1A. Hum. Mol. Genet. 20, 4891-4902.

Caron, A. Z., Haroun, S., Leblanc, S., Trensz, F., Guindi, C., Amrani, A. and Grenier, G. (2011). The proteasome inhibitor MG132 reduces immobilization-induced skeletal muscle atrophy in mice. BMC Musculoskelet. Disord. 12, 185.

Chang, N. C., Nguyen, M., Bourdon, J., Risse, P. A., Martin, J., Danialou, G., Rizzuto, R., Petrof, B. J. and Shore, G. C. (2012). Bcl-2-associated autophagy regulator Naf-1 required for maintenance of skeletal muscle. Hum. Mol. Genet. 21, 2277-2287.

Clarke, B. A., Drujan, D., Willis, M. S., Murphy, L. O., Corpina, R. A., Burova, E., Rakhillin, S. V., Stitt, T. N., Patterson, C., Latres, E. et al. (2007). The E3 Ligase MuRF1 degrades myosin heavy chain protein in desmamethylated-treated skeletal muscle. Cell Metab. 6, 376-385.

Cloc, A., Marcq, F., Takeda, H., Pirotton, D., Dordoir, X., Bibé, R., Bouix, J., Caimeft, F., Elsen, J. M., Eychenne, F. et al. (2006). A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat. Genet. 38, 813-818.

Cohen, S., Brault, J. J., Gygi, S. P., Glass, D. J., Valenzuela, D. M., Gartner, C., Latres, E. and Goldberg, A. L. (2009). During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitinylation. J. Cell Biol. 185, 1083-1095.

Cohen, S., Zhai, B., Gygi, S. P. and Goldberg, A. L. (2012). Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy. J. Cell Biol. 198, 575-589.

Combarb, L., Adegoke, O. A., Bedard, N., Baracos, V., Attaix, D. and Wing, S. S. (2005). USP19 is a ubiquitin-specific protease regulated in rat skeletal muscle during catabolic states. Am. J. Physiol. Endocrinol. Metab. 288, E693-E700.

Cong, H., Sun, L., Liu, C. and Tien, P. (2011). Inhibition of atrogin-1/MAFbx expression by adenosine-delivered small hairpin RNAs attenuates muscle atrophy in fasting mice. Hum. Gene Ther. 22, 313-324.

Cubi, A., Comille, K., Leibovitch, M. P., Poupon, A., Tintignac, L. A., Sanchez, A. M. and Leibovitch, S. A. (2010). The translation regulatory subunit eIF3f controls the kinase-dependent mTOR signaling required for muscle differentiation and hypertrophy in mouse. PLoS ONE 5, e8994.

Cuervo, A. M. (2008). Autophagy and aging: keeping that old bournemouth. Trends Genet. 24, 604-612.

de Alvaro, C., Torruel, T., Hernandez, R. and Lorenzo, M. (2004). Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J. Biol. Chem. 279, 17070-17078.

Demontis, F. and Perrimon, N. (2010). FOXO/4E-BP signaling in Drosophila muscles regulates organism-wide proteostasis during aging. Cell 143, 813-825.

Deval, C., Mordier, S., Obled, C., Bechet, D., Combaret, L., Attaix, D. and Ferrara, M. (2001). Identification of cathepsin L as a differentially expressed message in human muscle. J. Biol. Chem. 276, 22817-22824.

Deval, C., Mordier, S., Obled, C., Bechet, D., Combaret, L., Attaix, D. and Ferrara, M. (2001). Identification of cathepsin L as a differentially expressed message associated with skeletal muscle wasting. Biochem. J. 360, 143-150.

Dobrowolny, G., Aucello, M., Rizzuto, E., Beccaizzo, S., Mammuccari, C., Boncongioni, S., Belia, S., Wannenes, F., Nicoletti, C., Del Prete, Z. et al. (2008). Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. Cell Metab. 8, 429-435.

Dogra, C., Changotra, H., Wedhas, N., Qin, X., Wergedal, J. E. and Kumar, A. (2008). Tumor necrosis factor alpha activates nuclear factor kappaB acyltransferase 6 through the Akt/mTOR pathway. Cell 134, 575-589.

Dobrovolny, G., Aucello, M., Rizzuto, E., Beccaizzo, S., Mammuccari, C., Boncongioni, S., Belia, S., Wannenes, F., Nicoletti, C., Del Prete, Z. et al. (2008). Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. Cell Metab. 8, 429-435.

Dutta, G., Changotra, H., Wedhas, N., Qin, X., Wergedal, J. E. and Kumar, A. (2008). Tumor necrosis factor alpha activates nuclear factor kappaB acyltransferase 6 through the Akt/mTOR pathway. Cell 134, 575-589.
Fukuda, T., Roberts, A., Aeheart, M., Zaal, K., Ralston, E., Plotz, P. H. and Raben, N. (2006b). Autophagy and lysosomes in Pompe disease. *Autophagy* 2, 318-320.

Furuno, K., Goodman, M. N. and Goldberg, A. L. (1990). Role of different proteolytic systems in the degradation of muscle proteins during denervation atrophy. *J. Biol. Chem.* 265, 8550-8555.

Geng, T., Li, P., Yin, X. and Yan, Z. (2011). PGC-1α promotes nitric oxide antioxidant defenses and inhibits FOXO signaling against cardiac cachexia in mice. *Am. J. Pathol.* 178, 1738-1748.

Gomes, M. D., Lecker, S. H., Jago, R. T., Navon, A. M. and Goldberg, A. L. (2001). Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. *Proc. Natl. Acad. Sci. USA* 98, 14440-14445.

Gomis, R. R., Alarcón, C., He, W., Wang, Q., Seoane, J., Lash, A. and Massagüé, J. (2006). A FoxO-Smad synexpression group in human keratinocytes. *Proc. Natl. Acad. Sci. USA* 103, 12747-12752.

Goncalves, M. D., Pintilli, E. E., Balduzzi, A., Birnbaum, M. J., Lachey, J., Khurana, T. S. and Ahima, R. S. (2010). Akt deficiency attenuates muscle size and function but not the response to ActRIIB inhibition. *PLoS ONE* 5, e12707.

Greer, E. L., Dowlathshahi, D., Banko, M. R., Villen, J., Hoang, K., Blanchard, D., Gygi, S. P. and Brunet, A. (2007a). An AMPK-FOXO pathway mediates longevity induced by a novel method of dietary restriction in C. elegans. *Curr. Biol.* 17, 1646-1656.

Greer, E. L., Oskoui, P. R., Banko, M. R., Maniar, J. M., Gygi, M. P., Gygi, S. P. and Brunet, A. (2007b). The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. *J. Biol. Chem.* 282, 30107-30119.

Grobet, L., Pirott, D., Farnir, F., Poncelet, D., Royo, L. J., Brouwers, B., Christians, R., de la Iglesia, J. J., Brouwers, B., Christians, R., de la Iglesia, J. J. and Gygi, S. P. (2004). Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. *Mol. Cell. Biol.* 24, 233-239.

Grumati, P., Coletto, L., Sabatelli, P., Cescon, M., Angelini, A., Bertaggia, E., Blauw, U., Urciuolo, A., Tiepolo, T., Merlini, L. et al. (2010). Autophagy is defective in collagen VI-deficient muscles but is detrimental for collagen VI-deficient mice. *Autophagy* 7, 1415-1423.

Hanna, R. A., Quinsay, M. N., Orogo, A. M., Gygi, M. P., Gygi, S. P. and Brunet, A. (2011). Physical exercise stimulates autophagy in normal skeletal muscles. *Autophagy* 7, 426-428.

Hanna, R. A., Quinsay, M. N., Orogo, A. M., Gygi, M. P., Gygi, S. P. and Brunet, A. (2011b). Physical exercise stimulates autophagy in normal skeletal muscles but is detrimental for collagen VI-deficient muscles. *Autophagy* 7, 1415-1423.

He, C., Bassil, M. C., Moresi, V., Sun, K., Wei, Y., Zou, Z., An, Z., Loh, J., Fisher, J., Sun, Q. et al. (2012). Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. *Nature* 481, 511-515.

Hirosumi, H., Iwasa, K., Properties, C., and Hirosumi, H., Iwasa, K., Properties, C., and Hishiya, A., Iemura, S., Natsume, T., Takayama, S., Ikeda, K. and Watanabe, K. (2007a). A FoxO-Smad synexpression group in human keratinocytes. *Curr. Biol.* 17, 945-952.

Hishiya, A., Iemura, S., Natsume, T., Takayama, S., Ikeda, K. and Watanabe, K. (2007b). The energy sensor AMPK directly activates the autophagy-related protein Atg16L1 and regulates the response to ActRIIB inhibition. *PLoS ONE* 2, e151-175.

Kitamura, T., Kitamura, Y., Funahashi, Y., Shawber, C. J., Castrillon, D. H., Kollipara, R., DePinho, R. A., Kitajewski, J. and Accili, D. (2007). A Foxo/Notch interaction controls myogenic differentiation and fiber type specification. *J. Clin. Invest.* 117, 2477-2485.

Kline, W. O., Vanaro, F. J., Yang, H. and Bodine, S. C. (2007). Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol. *J. Appl. Physiol.* 102, 740-747.

Klionsky, D. J., Abellóvich, H., Agostinis, P., Agrawal, D. K., Aliev, G., Askew, D. S., Baba, M., Baehrrecke, E. H., Bahr, B. A., Ballabio, A. et al. (2008). Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. *Autophagy* 4, 151-175.

Komi, S., Yamazaki, K., Kuzuya, T., Takase, Y., Saito, Y., Nishida, K., Nishida, K., Nishida, K., Nishida, K. and Konno, S. (2012). Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. *PLoS ONE* 7, e1399-1404.

Lee, D. and Goldberg, A. (2011). Autophagy induction rescues myofiber degeneration. *Cell* 149, 274-293.

Leecher, S. H., Goldberg, A. L. and Mitch, W. E. (2006). Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. *J. Am. Soc. Nephrol.* 17, 1807-1819.

Lee, S. J. (2004). Regulation of muscle mass by myostatin. *Annu. Rev. Cell Dev. Biol.* 20, 61-86.

Lee, S. J. (2007). Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. *PLoS ONE* 2, e789.

Levy, S. J. and McPherron, A. C. (2011). Atrophy1/MAFbrc: what atrophy, hypertrophy, and cardiac failure have in common. *Circ. Res.* 109, 123-126.

Lee, S. J. and McPherron, A. C. (1999). Myostatin and the control of skeletal muscle mass. *Curr. Opin. Genet. Dev.* 9, 604-607.

Levy, S. J. and McPherron, A. C. (2001). Regulation of myostatin activity and muscle growth. *Proc. Natl. Acad. Sci. USA* 98, 9306-9311.

Lee, S. W., Dai, G., Hu, Z., Wang, X., Du, J. and Mitch, W. E. (2004). Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphorylidylinositol 3 kinase. *J. Am. Soc. Nephrol.* 15, 1537-1545.

Lee, J. H., Budanov, A. V., Park, E. J., Birse, R., Kim, T. E., Perkins, G. A., Ocor, K., Ellisman, M. H., Bodmer, R., Bier, E. et al. (2010). Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. *Science* 327, 1223-1228.

Levine, S., Nguyen, T., Taylor, N., Frischa, M. E., Budak, M. T., Rothenberg, P., Zhu, J., Sachdeva, R., Sonnad, S., Kaiser, L. R. et al. (2008). Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. *N. Engl. J. Med.* 358, 1327-1332.

Li, H. H., Kadar, V., Zhang, C., McDonough, H., Arya, R., Wang, D. Z. and Patterson, C. (2004). Atrogin-1/muscle atrophy F-box inhibitor has calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. *J. Clin. Invest.* 114, 1058-1071.

Liu, C. M., Yang, Z., Liu, C. W., Wang, R., Tien, P., Dale, R. and Sun, L. Q. (2007). Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. *Cancer Gene Ther.* 14, 945-952.

Lokiredy, S., McFarlane, C., Ge, X., Zhang, H., Sze, S. K., Sharma, M. and Kambadur, R. (2011). Myostatin induces degradation of sarcomeric proteins through a Smad3 signaling mechanism during skeletal muscle wasting. *Mol. Endocrinol.* 25, 1936-1949.

Malicdan, M. C., Noguchi, S., Nonaka, I., Saftig, P. and Nishino, I. (2008). lysosomal myopathies: an excessive build-up in autophagosomes is too much to handle. *Neuromuscul. Disord.* 18, 521-529.
Mammucari, C., Milan, G., Romanello, V., Masiero, E., Rudolf, R., Del Piccolo, P., Burden, S. J., Di Lisì, R., Sandri, C., Zhao, J. et al. (2007). FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 6, 458-471.

Masiero, E. and Sandri, M. (2010). Autophagy inhibition induces atrophy and myopathy in adult skeletal muscles. Autophagy 6, 307-314.

Masiero, E., Agatea, L., Mammucari, C., Blauw, R., Loro, E., Komatsu, M., Metzger, D., Reggiani, C., Schiaffino, S. and Sandri, M. (2009). Autophagy is required to maintain muscle mass. Cell Metab. 10, 507-515.

Massagué, J., Seoane, J. and Wotton, D. (2005). Smad transcription factors.

McFarlane, C., Plummer, E., Thomas, M., Hennebry, A., Ashby, M., Ling, N., Smith, (1997). Double muscling in cattle due to mutations in}

Morissette, M. R., Cook, S. A., Foo, S., McKoy, G., Ashida, N., Novikov, M., Scherrer-Moresi, V., Williams, A. H., Meadows, E., Flynn, J. M., Potthoff, M. J., McAnally, J., et al. (2005). FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128, 309-323.

Pankiv, S., Clausen, T. H., Lamark, T., Brech, A., Brun, J. A., Outzen, H., Øvervatn, A., Bjerck, G. and Johansen, T. (2007). p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J. Biol. Chem. 282, 24131-24145.

Park, Y. E., Hayashi, Y. K., Bonne, G., Arimura, T., Noguchi, S., Nonaka, I. and Nishida, E. (2009). Autophagic degradation of nuclear components in mammalian cells. Autophagy 5, 795-804.

Paul, P. K., Gupta, S. K., Bhatnagar, S., Panguluri, S. K., Darnay, B. G., Choi, Y. and Kumar, A. (2010). Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J. Cell Biol. 191, 1395-1411.

Paul, P. K., Bhatnagar, S., Mishra, V., Srivastava, S., Darnay, B. G., Choi, Y. and Kumar, A. (2012). The E3 ubiquitin ligase TRAF6 intercedes in starvation-induced skeletal muscle atrophy through multiple mechanisms. Mol. Cell. Biol. 32, 1248-1259.

Peng, X. D., Xu, P. Z., Chen, M. L., Hahn-Windgassen, A., Skeen, J., Jacobs, J., Sundararajan, D., Chen, W. S., Crawford, S. E., C., Coleman, K. G. et al. (2003). Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev. 17, 1352-1365.

Peterson, J. M., Bakkar, N. and Guttridge, D. C. (2011). NF-κB signaling in skeletal muscle mass and disease. Curr. Top. Dev. Biol. 96, 85-119.

Pliétri-Rouxel, F., Gentil, C., Vasilopoulos, S., Baas, D., Mouiel, E., Ferry, A., Vignaud, A., Houdré, C., Marty, I., Schaeffer, L. et al. (2010). DHPR alpha1s subunit controls skeletal muscle mass and morphogenesis. EMBO J. 29, 643-654.

Pulisperve, P., Rhee, J., Donovan, J., Walkay, C. J., Yoon, J. C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D. et al. (2003). Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 423, 550-555.

Raben, N., Hill, V., Shea, L., Takikita, S., Baum, R., Mizushima, N., Rašton, E. and Plotz, P. (2008). Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease. Hum. Mol. Genet. 17, 3897-3908.

Raffaelli, A., Milan, G., Masiero, E., Carnio, S., Lee, D., Lanfranchi, G., Goldberg, A. L. and Sandri, M. (2010). Jun8 transcription factor maintains skeletal muscle mass and promotes hypertrophy. J. Cell Biol. 191, 101-113.

Ramachandran, N., Munteanu, I., Wang, P., Aubourg, P., Ribe, J. J., Israel, N., Naranian, T., Parottos, P., Guo, R., Ren, Z. P. et al. (2009). VMA21 deficiency causes an autophagic myopathy by compromising V-ATPase activity and lysosomal acidification. Cell 137, 235-246.

Reed, S. A., Sandesara, B. P., Senf, S. M. and Judge, A. R. (2012). Inhibition of FoxO transcriptional activity prevents muscle fiber autophagy during cachexia and induces hypertrophy. FASEB J. 26, 987-1000.

Reisz-Porszegi, S., Bhasin, S., Artaza, J. N., Shen, R., Sinha-Hikim, I., Hogue, A., Fielder, T. J. and Gonzalez-Cadavid, N. F. (2003). Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. Am. J. Physiol. Endocrinol. Metab. 285, E876-E888.

Risson, V., Mazelin, L., Roceri, M., Sanchez, H., Moncollin, V., Corneloup, C., Richard-Bulteau, H., Vignaud, A., Baas, D., Defour, A. et al. (2009). Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. J. Cell Biol. 187, 859-874.

Romanello, V. and Sandri, M. (2010). Mitochondrial biogenesis and fragmentation as regulators of muscle protein degradation. Curr. Hypertens. Rep. 12, 433-439.

Romanello, V., Guadagnin, E., Gomes, L., Roden, I., Sandri, C., Petersen, Y., Milan, G., Masiero, E., Del Piccolo, P., Foretz, M. et al. (2010). Mitochondrial fission and remodelling contributes to muscle atrophy. EMBO J. 29, 1774-1785.

Rommel, C., Bodine, S. C., Clarke, B. A., Rossman, R., Nunez, L., Stitt, N. T., Yancopoulos, G. D. and Glass, D. J. (2001). Mediation of IGF-1-induced skeletal myocyte hypertrophy by PI3K/Akt/mTOR and PI3K/Akt/GSK3 pathways. Nat. Cell Biol. 3, 1009-1013.

Sachek, J. M., Ohtsuka, A., McLean, S. C. and Goldberg, A. L. (2004). IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am. J. Physiol. Endocrinol. Metab. 287, E591-E601.

Sachek, J. M., Hyatt, J. P., Raffaelli, A., Jagoe, R. T., Roy, R. R., Egerton, V. R., Becker, S. H. and Goldberg, A. L. (2007). Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J. 21, 140-155.

Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Becker, S. H. and Goldberg, A. L. (2004). FoxO transcription factors...
Mechanisms of muscle atrophy

induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117, 399-412.

Sandri, M., Lin, J., Handschin, C., Yang, W., Arany, Z. P., Lecker, S. H., Goldberg, A. L. and Spiegelman, B. M. (2008). PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA 105, 16260-16265.

Sartorelli, V. and Fulco, M. (2004). Molecular and cellular determinants of skeletal muscle atrophy and hypertrophy. Sci. STKE 2004, re11.

Sartori, R., Milan, G., Patron, M., Mammucari, C., Blaubu, B., Abraham, R. and Sandri, M. (2009). Smad2 and 3 transcription factors control muscle mass in adulthood. Am. J. Physiol. Cell Physiol. 296, C1248-C1257.

Schakman, O., Gilson, H. and Thissen, J. P. (2008). Mechanisms of glucocorticoid-induced myopathy. J. Endocrinol. 197, 1-10.

Schiaffino, S. and Hanzlikova, V. (1972). Studies on the effect of denervation in developing muscle. II. The lysosomal system. J. Ultrastruct. Res. 39, 1-14.

Schiaffino, S. and Mammucari, C. (2011). Regulation of skeletal muscle growth by the IGF-1-Akt/PI3K pathway: insights from genetic models. Skelet. Muscle 1, 4.

Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F. and Lee, S. J. (2004). Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med. 350, 2682-2688.

Schulze, P. C., Fang, J., Kassik, K. A., Gannon, J., Cupesi, M., MacGillivray, C., Lee, R. T. and Rosenthal, N. (2005). Transgenic overexpression of locally acting insulin-like growth factor-1 inhibitors ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction. Circ. Res. 97, 418-426.

Senf, S. M., Sandesara, P. B., Reed, S. A. and Judge, A. R. (1991). Proteins containing peptide sequences related to Lys-Phe-Glu-Arg-Gln are selectively depleted in liver and heart, but not skeletal muscle, of fasted rats. Biochem. J. 275, 165-169.

Shi, J., Luo, L., Eash, J., Ibebunjo, C. and Glass, D. J. (2011). FOXO1 regulates the IGF-1/Akt/PKB pathway prevents expression of muscle atrophy-induced ubiquitin ligases by FOXO homologues in skeletal muscle. J. Biol. Chem. 282, 8345-8347.

Shimizu, N., Yoshikawa, N., Ito, N., Maruyama, T., Suzuki, Y., Takeda, S., Nakae, J., Tagata, Y., Nishitani, S., Takehana, K. et al. (2011). Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab. 13, 170-182.

Song, Y. H., Li, Y., Du, J., Mitch, W. E., Rosenthal, N. and Delafontaine, P. (2005). Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J. Clin. Invest. 115, 451-458.

Southgate, A. U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S. and Glass, D. J. (2009). Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am. J. Physiol. Cell Physiol. 296, C1258-C1270.

Takano, K., Watanabe-Takano, H., Suetsugu, S., Kurita, S., Tsujita, K., Simura, S., Karatsu, T., Takenawa, T. and Endo, T. (2010). Nebulin and NiWASP cooperate to cause IGF-1-induced sarcomeric actin filament formation. Science 330, 1536-1540.

Takikita, S., Schreiner, C., Baum, R., Xie, T., Ralston, E., Plotz, P. H. and Raben, N. (2010). Fiber type conversion by PGC-1α activates lysosomal and autophagosomal biogenesis in both unaffected and Pompe skeletal muscle. PLoS ONE 5, e15239.

Tanaka, Y., Guhde, G., Suter, A., Eskenlin, E. L., Hartmann, D., Lüllmann-Rauch, R., Janssen, P. M., Blanz, J., von Figura, K. and Safitig, P. (2000). Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 406, 902-906.

Tintignac, L. A., Lagirand, J., Batonnet, S., Sirri, V., Leibovitch, M. P. and Leibovitch, S. A. (2005). Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J. Biol. Chem. 280, 2847-2856.

Trendelenburg, A. U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S. and Glass, D. J. (2009). Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am. J. Physiol. Cell Physiol. 296, C1258-C1270.

Wern, T., Rossi, S. G., Rotundo, R. L., Spiegelman, B. M. and Moraes, C. T. (2009). Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging. Proc. Natl. Acad. Sci. USA 106, 20405-20410.

Wing, S. S., Chiang, H. L., Goldberg, A. L. and Dice, J. F. (1991). Proteins containing peptide sequences related to Lys-Phe-Glu-Arg-Gln are selectively depleted in liver and heart, but not skeletal muscle, of fasted rats. Biochem. J. 275, 165-169.